ClinicalTrials.Veeva

Menu

SPME For Metabolomics And Concomitant Measurements Of Rocuronium Bromide Levels In Liver Transplantation

University Health Network, Toronto logo

University Health Network, Toronto

Status

Completed

Conditions

Liver Failure

Treatments

Drug: Rocuronium

Study type

Observational

Funder types

Other

Identifiers

NCT01404793
UHN REB 11-0325-BE

Details and patient eligibility

About

Standard anesthetic management of liver transplantation patients includes a general anesthetic using multiple drugs, including the neuromuscular relaxant rocuronium. Pharmacokinetic modelling of this agent has been poorly described during liver transplantation, which impacts on appropriate dosing of this agent within this population where plasma concentrations can vary with fluid shifts and hepatic drug metabolism during the various phases of liver transplantation. Plasma drug and drug metabolite concentrations will be measured using the technique of solid phase micro-extraction (SPME). Measuring and correlating the levels of rocuronium and other liver metabolites with the degree of post transplantation hepatic dysfunction may serve as a simple and cost-effective marker to aid diagnosis, identify those at risk of hepatic dysfunction and potentially grade the severity

Enrollment

28 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • First time liver transplant recipients above 18 years of age
  • Elective cadaveric or living donor liver transplant patients will be recruited

Exclusion criteria

  • All patients under 18 years of age
  • Unable to give consent

Trial design

28 participants in 1 patient group

Liver transplant recipient
Treatment:
Drug: Rocuronium

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems